FritsVan RheeMD

PubMed

• 269 citations
  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
  Saad Z. Usmani, Christoph Heuck, Alan Mitchell, Jackie Szymonifka, Bijay Nair
  Haematologica. 2012-11-01
• 361 citations
  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and i...
  Ichiro Hanamura, James P. Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra
  Blood. 2006-09-01
• 19 citations
  Making progress in treating multiple myeloma with total therapies : issue of complete remission and more
  Bart Barlogie, F. van Rhee, John D. Shaughnessy, Elias Anaissie, John Crowley
  Leukemia. 2008-08-01

Abstracts/Posters

• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all